Eli Lilly Weight Loss Drug

Eli Lilly, Weight Loss

Eli Lilly says weight-loss pill a candidate for speedy approval under new US program

Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's new national priority voucher, suggesting it is a strong candidate for a significantly accelerated approval review.

· 20h · on MSN

Lilly Ups Guidance on Weight Loss, Obesity Drugs’ Strength

· 1d · on MSN

Eli Lilly partners with Walmart to sell weight loss drug directly to patients nationwide

Fierce Healthcare

Eli Lilly, Walmart launch retail pick-up option for weight loss drug Zepbound

Pharma giant Eli Lilly tapped Walmart to offer in-store pickups of Zepbound vials, marking the first retail collaboration for ...

1don MSN

Eli Lilly’s stock jumps as Zepbound sales nearly triple at lower prices

Eli Lilly’s stock rallies, as Zepbound sales nearly tripled, leading to record revenue and a raised full-year outlook.

1don MSN

In Lilly vs Novo obesity drug battle, Trump price talks grab focus

As obesity drug heavyweights Eli Lilly and Novo Nordisk gear up to release results for the third quarter, investors are ...

3don MSN

Down 15%, Should You Buy the Dip on Eli Lilly?

With a market cap of around $730 billion, Eli Lilly ( LLY 0.92%) is one of the largest pharmaceutical companies on planet ...

Fierce Pharma

Innovent, Lilly's mazdutide trumps Novo's semaglutide in head-to-head diabetes, weight loss study

An experimental GLP-1/glucagon (GCP) dual receptor agonist from Eli Lilly and its Chinese partner Innovent has bested Novo Nordisk’s reigning GLP-1 semaglutide in a phase 3 study across both b | ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results